SoFi earlier this year announced that it would go public through a SPAC merger. The company has high aspirations, but can it deliver?
Playing Xbox Series X games in 8K, or 4K at 120Hz refresh rates is causing problems with some receivers from Yamaha, Denon and Marantz.
Coronavirus in India Latest News LIVE Updates: The Central government Thursday moved the apex court against an order of the Karnataka High Court asking it to increase daily liquid medical oxygen allocation for state from present 965 MT to 1200 MT for treating COVID-19 patients
Tesla Inc told a California regulator that it may not achieve full self-driving technology by the end of this year, a memo by the California Department of Motor Vehicles (DMV) showed. Tesla CEO Elon Musk said during an earnings conference call in January that he was "highly confident the car will be able to drive itself with reliability in excess of human this year." Tesla has also rolled out what it describes as a "beta" version of its "full self-driving" (FSD) program to a limited number of employees and customers since October, and Musk has touted the capability on Twitter.
The Alabama Legislature Thursday gave final approval to a bill that would create a statewide medical marijuana program, following two historic votes.
China's exports growth unexpectedly picked up in April, official data showed on Friday, as the world's second-largest economy extended its recovery from the COVID-19 pandemic. Exports in dollar terms surged 32.3% from a year earlier to $263.92 billion, according to China's General Administration of Customs, beating analysts' forecast of 24.1% and the 30.6% growth reported in March. China ran a trade surplus of $42.85 billion for the month, customs said, wider than a $28.1 billion surplus tipped in the Reuters poll.
Ludhiana (Punjab) [India], May 7 (ANI): The Shiromani Gurdwara Parbandhak Committee (SGPC) on Thursday opened a 25-bed COVID-19 care center at Gurdwara Manji Sahib in Alamgir which will provide free health care to coronavirus patients.
SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee (“Committee”) on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). In the final part of the public meeting, the Committee voted on three questions presented by the FDA: The Committee vote split 9-9 on the first question, whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)).On the second question, the Committee voted 10-8 that the safety profile of avacopan is adequate to support approval of avacopan for the treatment of adult patients with AAV (GPA and MPA). In the third and final question, the Committee voted 10-8 that the benefit-risk profile is adequate to support approval of avacopan at the proposed dose of 30 mg twice daily for the treatment of adult patients with AAV (GPA and MPA). “We are grateful to the Committee for their careful deliberations and look forward to working with the FDA as its review of our application continues,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Discussion from patients and clinicians during the public forum portion of the meeting underscored the need for new treatment options.” “We hope that the FDA will take into account the dire situation faced by patients living with this debilitating disease,” said Joyce Kullman, Executive Director, Vasculitis Foundation. ”ANCA vasculitis flares can lead to kidney failure and death; current therapy all too often causes serious, even fatal, side effects; and patients suffer a lower quality of life due to the disease and to the way it is treated.” FDA Advisory Committees provide the FDA with independent opinions and non-binding recommendations from outside medical experts. While the FDA will consider the opinions expressed and recommendations made by the Advisory Committee, the FDA will make a decision regarding whether to approve the NDA for avacopan in ANCA-associated vasculitis following completion of its review process. About ADVOCATE and ANCA-Associated VasculitisThe ADVOCATE trial of avacopan was a global, randomized, double-blind, active-controlled, double-dummy Phase III trial of 331 patients with ANCA-associated vasculitis in 20 countries. Eligible study subjects were randomized to receive avacopan plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate) or prednisone plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate). ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. Currently, treatment for ANCA-associated vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids (steroids) for prolonged periods of time, which can be associated with significant clinical risk including death from infection. About AvacopanAvacopan is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis and other complement-driven autoimmune and inflammatory diseases. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA-associated vasculitis. Current therapies for ANCA-associated vasculitis and other related illnesses typically include broad immunosuppression with daily doses of glucocorticoids (steroids) such as prednisone or methylprednisone, which can cause significant illness and even death. Avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan drug designation for ANCA-associated vasculitis and C3G. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. ChemoCentryx is responsible for the discovery and development of avacopan and owns and retains the commercial rights to the drug in the United States. ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan in markets outside of the U.S. About ChemoCentryxChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. Forward-Looking StatementsChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the timing of anticipated PDUFA date for the avacopan NDA for the treatment of ANCA-associated vasculitis, the achievement of anticipated goals and milestones, whether avacopan will be approved by the FDA for the treatment of ANCA-associated vasculitis, whether avacopan will be an effective treatment in other indications such as C3G or severe HS, and whether the Company's drug candidates will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC on March 11, 2021 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Contacts:Susan M. KanayaExecutive Vice President,Chief Financial and Administrative Officerinvestor@chemocentryx.com Media:Stephanie Tomei408.email@example.com Investors:Burns McClellan, Inc.Lee Roth212.firstname.lastname@example.org
Gabrielle Union and her husband Dwyane Wade have been going strong for more than a decade
Well, “good-ish” Elon Musk will make his SNL debut this Saturday, which comes out the day before Mother’s Day, and in a promo clip for the episode he promised to bring his best in honor of his mom. In the promo for the upcoming May 8 episode, Musk and musical guest Miley Cyrus were joined by cast member Cecily Strong. Musk told viewers from behind a bank robber-esque black bandana, “I am a wild card, so there’s no telling what I might do.” Cyrus agreed, and added, “same here. Rules, no thanks.” Then Strong reminded them both that it’s the show’s 2021 Mother’s Day episode and both their moms were going to be in the audience. After that, both Musk and Cyrus quickly changed their tune and Cyrus joked, “forget what I said.” “I will be good-ish,” Musk said before the clip ended. Both Miley and Elon are tight with their moms — Cyrus matriarch Tish Cyrus has managed Miley for 16 years and recently designed Miley’s new 6,800 square-foot home in Southern California. Elon’s mom, Maye Musk, is a fierce supporter of her son’s seemingly never-ending tech ventures and told People Magazine that she knew Elon was a “genius” by the time he’d turned three. While some “SNL” cast members, like Bowen Yang, Aidy Bryant and Chris Redd don’t seem too thrilled about the billionaire hosting this upcoming episode, some fans — and fellow cast member Pete Davidson — are pretty amped to see Musk step into, well, whatever characters he and the “SNL” cast figure out for him. Check out the teaser for Musk’s upcoming “SNL” episode below. ELON MUSK. MILEY CYRUS.THIS SATURDAY pic.twitter.com/6miGBj90XJ— Saturday Night Live – SNL (@nbcsnl) May 7, 2021 Read original story ‘SNL': Elon Musk Promises to Be Good in Promo for Mothers Day Episode (Video) At TheWrap
BlockBank leverages Artificial Intelligence, adding it to the traditional banking and DeFi system making the entire ecosystem more secure, private, and decentralized. The platform will be AI-powered, which means it will monitor and understand social intelligence, risk mitigation, analytics, batched transactions, and smart contracts.
Could this be the end of the series?
PENN earnings call for the period ending March 31, 2021.
Good morning, everyone, and welcome to the Manitowoc conference call to review the company's first-quarter 2021 financial performance and business update, as outlined in last evening's press release. Participating on the call today are Aaron Ravenscroft, president and chief executive officer; and David Antoniuk, executive vice president and chief financial officer.
Ladies and gentlemen, thank you for standing by, and welcome to ADTRAN's First Quarter 2021 Earnings Release Conference Call. During the course of the conference call, ADTRAN representatives expect to make forward-looking statements, which reflect management's best judgments based on factors currently known.
Good morning and welcome everyone to our first quarter 2021 earnings call. With me in the office or on the call today include Carey Hendrickson, our CFO; Graham Reeve and Glenn McDowell, our COOs; Binstein, our General Counsel; and Jon Bates, our Vice President and Controller.
Image source: The Motley Fool. Rayonier Inc (NYSE: RYN)Q1 2021 Earnings CallMay 6, 2021, 10:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome, and thank you for joining Rayonier's First Quarter 2021 Teleconference Call.
The all-Premier League encounter between Manchester City and Chelsea is scheduled to take place in Istanbul.
Japan to extend Covid emergency in Tokyo as Olympics loom. Government admits restrictions that had been due to end on 11 May have failed to stop rising infections
TORONTO — Sheldon Keefe saw a different Auston Matthews back in January. Creating offence had never been a problem for the Maple Leafs' star sniper. It was everything else about the 23-year-old's game during a tough training camp that stood out to Toronto's head coach. "He's come in, I think, on a mission," Keefe said. "He's put in such great work defensively away from the puck that you want to see him reach the goals he has for himself. "And they're lofty goals, but clearly he keeps setting the bar even higher." That continued on a milestone Thursday night. Matthews scored for a league-leading 40th time in just his 49th game as the North Division-topping Leafs jump on Montreal early in a 5-2 victory over the Canadiens. "It means a lot," Matthews said of reaching 40 goals for the third time in his five NHL seasons. "It's a team sport, so there's a lot that goes into it." Frank Mahovlich is the only player in franchise history to score 40 goals in fewer games, hitting the mark in 48 contests in 1960-61. Matthews, who tallied 47 in 70 games before the 2019-20 campaign was suspended because of the COVID-19 pandemic, required the fewest games to hit 40 goals since Pavel Bure reached the number in 48 outings back in 1999-00 with the Florida Panthers. "It's incredible," Toronto captain John Tavares said. "He makes it look so easy. It's unreal to watch. It's a testament to him and his work ethic." With the Leafs leading 4-2 in the third period, Matthews took a feed from Mitch Marner and wired a shot past Jake Allen to extend his goal streak to five games. The No. 1 pick at the 2016 NHL draft also has a personal five-game goal run against Montreal. "At this level, in this league, it's extremely hard to score," Tavares added. "To do it as often as he does, as consistent as he is, and as dominant as he is, it's extremely impressive." Marner and Tavares, with a goal and an assist each, Alex Galchenyuk and Pierre Engvall also scored for Toronto (34-13-6). Jack Campbell made 20 saves, while Jake Muzzin added two assists. Campbell improved to 16-2-2 in 2021, giving him the most wins ever by a Leafs netminder through 20 games. "It's pretty cool," he said. "It just speaks volumes of how well our team's playing." Cole Caufield and Artturi Lehkonen replied for Montreal (24-20-9). Cayden Primeau allowed four goals on 15 shots in the opening 20 minutes before being replaced by Allen, who finished with 19 saves. The Leafs improved to 6-2-1 against the Canadiens in 2021 after falling 3-2 in overtime at the Bell Centre on Monday. "They just jumped all over us," Montreal defenceman Ben Chiarot said. "We were slow out of the gate." Likely first-round playoff opponents, the Original Six teams conclude their 10-game regular-season series Saturday back at Scotiabank Arena. Montreal had a chance to clinch a post-season spot Thursday, and still trails Winnipeg by two points for third in the division with three games left on its schedule. The Jets, who secured a post-season berth Wednesday, have four home dates left on the docket. Toronto was minus injured forwards Zach Hyman (knee) and Nick Foligno (upper-body), as well as defenceman Zach Bogosian (shoulder), but got blue-liner Justin Holl (face) back after he missed Monday's loss. Tomas Tatar (lower-body) returned to the Montreal lineup following a five-game absence, but the Canadiens were still without starting goalie Carey Price (concussion), captain Shea Weber (upper-body), forward Paul Byron (lower-body) and winger Jonathan Drouin (personal). The Leafs opened the scoring just 16 seconds into Thursday when Galchenyuk whipped a backhand from the slot past Primeau for his fifth goal of the season — and first against the team that drafted him third overall in 2012. Playing the second of a back-to-back following a 5-1 loss in Ottawa, Montreal went down 2-0 at 3:24 when Tavares picked up a rebound to bury his 18th. Engvall then got in on the action at 10:38 with his fifth as Toronto scored on three of its first eight shots against Montreal's rookie third-string goalie. "We were flat in front of him," Chiarot said. "Didn't give him any help." Marner continued the onslaught with 2:39 left in the period when the seas parted and he deked around a helpless Primeau before smoothly backhanding home his 19th from below the goal line. "That's just the guys buzzing," Campbell said of Toronto's barrage. "Love seeing that ... it gives the team a ton of confidence." Allen replaced Primeau to start the second, and the visitors came close to getting one back on an early power play, but Holl cleared a loose puck off Campbell's line. Toronto appeared to go up 5-0 midway through the period only to have Ilya Mikheyev's one-timer waved off because Stefan Noesen, who was making his Leafs debut, was in Allen's crease. Montreal finally got on the board with 6:30 left in the period when Caufield scored his third — the rookie bagged the OT winner against Campbell in Montreal on Monday for the second extra-time goal of his young career — after Rasmus Sandin had his pocket picked. Lehkonen added his sixth on a rebound to make it 4-2 just 3:04 into the third, but Toronto held firm from there before Matthews put things to bed at 15:41. "We had a real challenging training camp," Keefe recalled. "When a player of Auston's calibre comes in and is first of all prepared for it, but secondly goes out on the ice and is leading the charge for our group in terms of work ethic and competitiveness, attention to detail, it was very clear he was ready to bring his game to another level. "He's not going to slow down ... he's just going to keep pushing himself and our team." This report by The Canadian Press was first published May 6, 2021. ___ Follow @JClipperton_CP on Twitter Joshua Clipperton, The Canadian Press
The Australian Sports Commission has apologized to athletes treated inappropriately at the Australian Institute of Sport following an independent review into gymnastics heard evidence of a toxic culture that contributed to physical, emotional and sexual abuse of young athletes. Multiple athletes detailed their negative experiences at the AIS in the report, including the organization’s heavy focus on the ideal body. One interviewee said: “As far as the AIS was concerned, the smaller and more petite you were, the better gymnast you made."